Table 3.
Cure rates and missing patients in the all-treated target and clinically evaluable populations
| |
Telavancin |
Standard therapy |
95% CI for the difference (telavancin–standard therapy) |
|---|---|---|---|
| n/N (%) | n/N (%) | ||
| All-treated target |
|
|
|
| End-of-therapy visit |
11/15 (73%) |
15/16 (94%) |
(–44.4, 7.8) |
| Follow-up visit |
9/15 (60%) |
14/16 (88%) |
(–53.6, 4.5) |
| Test-of-cure visit |
8/15 (53%) |
11/16 (69%) |
(–45.9, 18.5) |
| Clinically evaluable |
|
|
|
| End-of-therapy visit |
8/8 (100%) |
9/9 (100%) |
(–26.1, 24.3) |
| Follow-up visit |
7/8 (88%) |
9/9 (100%) |
(–41.0, 19.1) |
| Test-of-cure visit |
7/8 (88%) |
8/9 (89%) |
(–35.5, 31.9) |
| MRSA |
5/5 (100%) |
4/4 (100%) |
- |
| MSSA | 2/3 (67%) | 4/5 (80%) | - |
CI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.